{"title":"Ganoderma lucidum ethanolic extract for the treatment of androgenic alopecia in rats with testosterone-induced Baldness.","authors":"Poonam C. Rahangdale, A. Wankhade","doi":"10.55940/medphar202343","DOIUrl":null,"url":null,"abstract":"Background: Alopecia is a widespread hair loss condition affecting numerous individuals worldwide. This study aims to investigate the potential hair growth-promoting properties of a preparation containing an ethanolic extract of Ganoderma lucidum and its primary components in a model of testosterone-induced alopecia. Aim: The objective of this research is to assess the effects of Ganoderma lucidum extract on hair regeneration using a testosterone-induced alopecia model. Materials and Methods: The study was conducted using five groups of rats: negative control group (n = 6), positive control group (n = 6), testosterone plus minoxidil 2% (n = 6), testosterone and ethanolic extract of Ganoderma lucidum extract (10 mg/kg) (n = 6), and testosterone and ethanolic extract of Ganoderma lucidum extract (15 mg/kg). To induce alopecia, subcutaneous testosterone (1 mg/kg SC) was administered daily to all groups except the negative control group for 21 consecutive days. After 21 days, Anagen/telogen (A/T) ratio and the number of follicles were measured and recorded. Results: The standard group, treated with minoxidil 2%, showed a higher anagen/telogen (A/T) ratio, follicular density, and hair length compared to the positive control group. The groups treated with ethanolic extract of Ganoderma lucidum at 10mg/kg and 15mg/kg displayed increased anagen/telogen ratio and improved hair follicle quantity and morphology compared to the positive control group. Furthermore, the group treated with 15mg/kg of the extract showed more favorable outcomes compared to the 10mg/kg group. These results were comparable to the effects of the commonly prescribed drug, Minoxidil 2%, used to promote hair growth in individuals with androgenetic alopecia. Conclusion: The preparation containing an ethanolic extract of Ganoderma lucidum, especially at a concentration of 15mg/kg, demonstrated significant hair growth-promoting effects in the testosterone-induced alopecia model. Our findings suggest the potential of Ganoderma lucidum extract as a possible treatment for alopecia and merit further exploration for therapeutic applications.","PeriodicalId":7822,"journal":{"name":"安徽医药","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"安徽医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55940/medphar202343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Alopecia is a widespread hair loss condition affecting numerous individuals worldwide. This study aims to investigate the potential hair growth-promoting properties of a preparation containing an ethanolic extract of Ganoderma lucidum and its primary components in a model of testosterone-induced alopecia. Aim: The objective of this research is to assess the effects of Ganoderma lucidum extract on hair regeneration using a testosterone-induced alopecia model. Materials and Methods: The study was conducted using five groups of rats: negative control group (n = 6), positive control group (n = 6), testosterone plus minoxidil 2% (n = 6), testosterone and ethanolic extract of Ganoderma lucidum extract (10 mg/kg) (n = 6), and testosterone and ethanolic extract of Ganoderma lucidum extract (15 mg/kg). To induce alopecia, subcutaneous testosterone (1 mg/kg SC) was administered daily to all groups except the negative control group for 21 consecutive days. After 21 days, Anagen/telogen (A/T) ratio and the number of follicles were measured and recorded. Results: The standard group, treated with minoxidil 2%, showed a higher anagen/telogen (A/T) ratio, follicular density, and hair length compared to the positive control group. The groups treated with ethanolic extract of Ganoderma lucidum at 10mg/kg and 15mg/kg displayed increased anagen/telogen ratio and improved hair follicle quantity and morphology compared to the positive control group. Furthermore, the group treated with 15mg/kg of the extract showed more favorable outcomes compared to the 10mg/kg group. These results were comparable to the effects of the commonly prescribed drug, Minoxidil 2%, used to promote hair growth in individuals with androgenetic alopecia. Conclusion: The preparation containing an ethanolic extract of Ganoderma lucidum, especially at a concentration of 15mg/kg, demonstrated significant hair growth-promoting effects in the testosterone-induced alopecia model. Our findings suggest the potential of Ganoderma lucidum extract as a possible treatment for alopecia and merit further exploration for therapeutic applications.